| Sep 5 |
Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
|
| Aug 28 |
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
|
| Aug 27 |
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
|
| Aug 26 |
Regeneron Stock: Valuation Now Demands More Growth
|
| Aug 26 |
Regeneron gains European approval for bispecific lymphoma drug
|
| Aug 26 |
Regeneron’s cancer therapy gets EU approval
|
| Aug 26 |
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
|
| Aug 26 |
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
|
| Aug 23 |
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
|
| Aug 21 |
FDA declines to approve Regeneron’s linvoseltamab amid manufacturing issues
|
